| Code | CSB-RA020067MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody B-013, targeting ROR1 (Receptor Tyrosine Kinase-like Orphan Receptor 1). ROR1 is an oncofetal surface antigen that plays a critical role in embryonic development but exhibits minimal expression in normal adult tissues. This receptor is aberrantly expressed in various hematological malignancies and solid tumors, including chronic lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, and certain breast and ovarian cancers. ROR1 contributes to cancer cell survival, proliferation, and metastasis through activation of non-canonical WNT signaling pathways, making it an attractive therapeutic target and biomarker in oncology research.
The B-013 reference antibody has been extensively utilized in cancer research to investigate ROR1 expression patterns, signaling mechanisms, and its potential as a therapeutic target. This biosimilar provides researchers with a reliable tool for studying ROR1-mediated oncogenic processes, evaluating tumor cell characteristics, and developing novel immunotherapeutic strategies. It supports investigations into antibody-dependent cellular cytotoxicity mechanisms and targeted cancer therapy development.
There are currently no reviews for this product.